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Background: The objective of this study was to report our institutional experience with 
Gamma Knife® Radiosurgery (GKRS) in the treatment of patients with brain metastases.
Methods: Retrospectively collected demographic and clinical data on 126 patients 
with intracranial metastases were reviewed. The patients in our study underwent GKRS 
at Vidant Medical Center between 2009 and 2014. Kaplan–Meier curves were used 
to compare survival based on clinical characteristics for univariate analysis, and a Cox 
proportional hazards model was used for multivariate analysis.
results: The median age of the patient population was 62 years. Medicare patients 
constituted 51% of our patient cohort and Medicaid patients 15%. The most common 
tumor histologies were non-small cell lung cancer (50%), breast cancer (12.7%), and 
melanoma (11.9%). The median overall survival time for all patients was 5.8 months. 
Patients with breast cancer had the longest median survival time of 9.15 months, while 
patients with melanoma had the shortest median survival time of 2.86  months. On 
univariate analysis, the following factors were predictors for improved overall survival, 
ECOG score 0 or 1 vs. 2 or greater (17.0 vs. 1.8 months, p < 0.001), controlled extra-
cranial disease vs. progressive extracranial disease (17.4 vs. 4.6 months, p = 0.0001), 
recursive partitioning analysis Stage I vs. II–III (18.2 vs. 6.2 months, p < 0.007), multiple 
GKRS treatments ( p = 0.002), prior brain metastasectomy ( p = 0.012), and prior che-
motherapy ( p = 0.021). Age, ethnicity, gender, previous external beam radiation therapy, 
number of brain metastases, and hemorrhagic vs. non-hemorrhagic tumors were not 
predictors of longer median survival time. Number of metastatic brain lesions of 1–3 vs. 
≥4 ( p = 0.051) and insurance status of Medicare/Medicaid vs. commercial insurance 
approached significance (13.7 vs. 6.8 months, p = 0.08). On multivariate analysis, ECOG 
performance status 0–1 ( p < 0.001), multiple GKRS treatments ( p = 0.003), and control 
of extracranial disease ( p = 0.001) remained significant predictors of survival.
conclusion: ECOG score, control of extracranial disease, and multiple GKRS treatments 
are predictors of longer median survival following GKRS in our patient population. GKRS 
is an effective treatment for brain metastases, but these factors may be considered in 
patient selection for GKRS.
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inTrODUcTiOn
As advances are made in surgical oncology, chemotherapy, and 
radiotherapy, median survival times for cancer patients continue 
to improve. Consequently, there are increasing numbers of 
patients presenting with brain metastases (1). Brain metastases 
are the most common brain tumor in adults, developing in about 
10–40% of adult cancer patients (2). Lung cancer, melanoma, 
breast cancer, colorectal cancer, and renal cell cancer are the most 
common sources of brain metastases (3). Stereotactic radiosur-
gery (SRS) including Gamma Knife® Radiosurgery (GKRS) is 
one strategy for treating patients with limited metastatic disease 
to the brain or in patients who have recurrent brain metastasis 
after prior whole-brain radiotherapy (WBRT). The aims of treat-
ment are palliation of neurological symptoms, maintenance of 
performance status (PS), and local control of metastatic disease. 
The benefit of GKRS is reduction of radiation to the surrounding 
normal brain parenchyma, which may thereby reduce neuro-
logical toxicities when compared to WBRT (4, 5) or which may 
improve local control when used in conjunction with WBRT (6) 
or surgery (7).
Despite advances in treatment, the prognosis for brain metas-
tases remains poor. Many factors including tumor histology, 
control of extracranial disease, and PS impact a patient’s overall 
survival (8). It has been reported that uninsured and underin-
sured cancer patients often have delayed diagnosis and inferior 
outcomes (9–11). Our institutional series is unique in that a 
larger percentage of our patient population is African-American, 
on Medicaid or on Medicare compared to previous publications 
reporting health disparities in patients treated for brain metasta-
ses (10, 11). The purpose of this study is to examine the impact 
of demographic and clinical characteristics on overall survival in 




This study reviews the experience of using GKRS in the treatment of 
brain metastases at the Brody School of Medicine at East Carolina 
University/Vidant Medical Center. We received University and 
Medical Center Institutional Review Board (UMCIRB) approval 
to conduct a retrospective review on the patients treated for 
metastatic brain lesions using the Gamma Knife (GK) by East 
Carolina University physicians at Vidant Medical Center between 
the years 2009 and 2014. A waiver of informed consent was 
granted by the UMCIRB, which functions to protect the rights 
and welfare of human subjects in research at our institution. All 
patients with a treatment diagnosis of metastatic disease to the 
brain were included in this review. Histologic confirmation of the 
cancer diagnosis was a requirement for inclusion.
stereotactic radiosurgery
The Leksell Gamma Knife Perfexion (Elekta AB, Stockholm, 
Sweden) was used for the SRS. Patients were treated on both 
an outpatient and inpatient basis. All patients were treated with 
frame-based immobilization and MRI-based treatment planning, 
with plans developed under the supervision of a radiation oncolo-
gist, a medical physicist, and a neurosurgeon. The radiation dose 
was contingent on tumor diameter/volume, proximity to critical 
structures, history of prior surgery, and history of prior radia-
tion treatment. Single-fraction SRS was used in all cases in this 
review. Radiation doses ranged from 10 to 24 Gy with a median 
dose of 20  Gy. The first follow-up was planned for 4–6  weeks 
after GKRS, and subsequent follow-up was generally planned at 
3-month intervals. GKRS for patients with prior metastasectomy 
was delivered to the surgical cavity with margin. Patients with 
any form of insurance (Medicare, Medicaid, or private insurance) 
were accepted for treatment in our program, some patients with 
no insurance were also treated, although at our institution many 
of these patients received SRS using a separate robotic-based 
system due to the availability of a more flexible payment with 
that modality.
Data collection/statistical analysis
The clinical characteristics collected in the study included ECOG 
PS, control of extracranial disease, recursive partitioning analysis 
(RPA) class (12), number of GKRS treatments, prior metasta-
sectomy, prior external beam radiotherapy to the brain, prior 
chemotherapy, concurrent chemotherapy, hemorrhagic metas-
tasis, number of brain metastases, histology, insurance status, 
gender, age, and ethnicity. Overall survival time was calculated 
from the time of treatment with first radiosurgery until the date 
of death from any cause. For surviving patients, the survival time 
was censored at the date of last follow-up. Survival was estimated 
by use of the Kaplan–Meier method. Local control and brain 
control were calculated from the time of initial GKRS within the 
study period until clear radiographic failure at the treated site 
and elsewhere outside the SRS field in the brain, respectively. 
Descriptive statistics were used to describe demographic and 
clinical characteristics. Univariate analysis was performed using 
the log-rank test to compare overall survival between patient 
groups within a factor. A Cox-proportional hazards model was 
used for multivariate analysis on all clinical factors that were 
significant or approached significance (p < 0.1) in the univariate 
analysis. All statistical analyses were performed using MedCalc® 
version 12.6.0.0.
resUlTs
One hundred and twenty-six patients were identified and 
included in this review. Demographic and clinical characteristics 
of the patients are presented in Table 1. The median patient age at 
treatment was 62 years (range 28–86 years). Non-small cell lung 
carcinoma (NSCLC) was the most common histologic diagnosis, 
followed by breast cancer and melanoma.
The median overall survival time for the entire cohort was 
5.8 months (range 0.1–64.1 months) from initial treatment with 
GKRS. The results of the univariate analysis of overall survival 
based on clinical characteristics are described in Table  2. 
Patients with breast cancer had the longest median survival 
of 9.15  months, while patients with melanoma had the short-
est median survival of 2.86  months. On univariate analysis, 
TaBle 2 | Univariate analysis of median overall survival time following 
gKrs by clinical characteristics.
clinical characteristics Median survival 
(months)
p-Value
ECOG 0 or 1 vs. ≥2 17.0 vs. 1.8 0.0001
Controlled vs. uncontrolled extracranial disease 17.4 vs. 4.6 0.0001
RPA Stage I vs. RPA ≥II 18.2 vs. 6.2 0.0007
Multiple GKRS sessions vs. one GKRS session 31.0 vs. 7.0 0.002
Prior metastasectomy vs. no prior metastasectomy Median not 
reached vs. 7.1
0.012
Prior chemotherapy vs. no prior chemotherapy 15.3 vs. 5.2 0.021
Less than 4 metastases vs. ≥4 metastases 15.2 vs. 6.6 0.051
Breast cancer vs. all other histologies 20.4 vs. 8.9 0.08
Commercial insurance or Medicare vs. Medicaid 
or uninsured
13.7 vs. 6.8 0.08
Female vs. male 15.4 vs. 7.0 0.10
Caucasian vs. non-Caucasian 13.7 vs. 10.1 0.89
GKRS, Gamma Knife® Radiosurgery.
TaBle 1 | Patient population demographics and clinical characteristics.







Commercial insurance 41 (32.5)
Medicaid 19 (15.1)
Uninsured 2 (1.6)
Single metastasis 48 (38.1)
Multiple metastases 78 (61.9)
Controlled extracranial disease 68 (54.0)





ECOG 0 36 (28.6)
ECOG 1 53 (42.1)
ECOG 2 37 (29.3)
RPA Stage I 40 (31.7)
RPA Stage II 53 (42.1)
RPA Stage III 33 (26.2)
GPA Score 0.0–1.0 13 (10.3)
GPA Score 1.5–2.0 50 (39.7)
GPA Score 2.5–3.0 47 (37.3)
GPA Score 3.5–4.0 16 (12.7)
1 brain lesion 45 (35.7)
2 or 3 lesions 56 (44.4)
4 or more lesions 25 (19.9)
Multiple GKRS sessions 13 (10.3)
One GKRS session 113 (89.7)
Prior brain surgery 18 (14.3)
No prior brain surgery 108 (85.7)
Median age (range) 62 years (range 28–86)
Median survival (range) 5.8 months (range 0.1–64.1)
Data are frequency (%) unless otherwise stated.
NSCLC, non-small cell lung carcinoma; RPA, recursive partitioning analysis; GKRS, 
Gamma Knife® Radiosurgery.
TaBle 3 | cox proportional hazards model of overall survival by the 
covariants identified as significant or near-significant on univariate 
analysis.
covariant p-Value
ECOG 0 or 1 vs. ≥2 0.0001
Controlled vs. uncontrolled extracranial disease 0.001
Multiple GKRS sessions vs. one GKRS session 0.003
Prior metastasectomy vs. no prior metastasectomy 0.09
Breast vs. all other histologies 0.11
Less than 4 metastases vs. ≥4 metastases 0.38
RPA Stage I vs. RPA ≥II 0.41
Commercial insurance or Medicare vs. Medicaid or 
uninsured
0.49
Prior chemotherapy vs. no prior chemotherapy 0.88
GKRS, Gamma Knife® Radiosurgery; RPA, recursive partitioning analysis.
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predictors for improved overall survival included ECOG PS 0–1 
vs. ≥2 (17.0 vs. 1.8 months, p < 0.001), controlled vs. uncontrolled 
extracranial disease (17.4 vs. 4.6 months, p < 0.001), RPA Stage I 
vs. II–III (18.2 vs. 6.2 months, p < 0.007), multiple GKRS treat-
ments vs. one GKRS treatment (31.0 vs. 7.0 months, p = 0.002), 
prior brain metastasectomy vs. none (median not reached vs. 
7.1 months, p = 0.012), and prior chemotherapy vs. none (15.3 vs. 
5.2 months, p = 0.021). The number of metastatic lesions of 1–3 
vs. ≥4 approached significance (15.2 vs. 6.6 months, p = 0.051), 
as did tumor histology of breast cancer vs. all other histologies 
(p  =  0.08). Insurance status of Medicare/Medicaid vs. com-
mercial insurance approached significance (13.7 vs. 6.8 months, 
p = 0.08). Previous external beam radiation therapy, concurrent 
chemotherapy, hemorrhagic metastases, gender, and age were not 
significant predictors of overall survival. Ethnicity (Caucasian 
vs. non-Caucasian, p  =  0.89) was not a statistically significant 
predictor of improved survival time. Only 74 patients (59%) had 
postradiosurgery MRIs available for review, of these patients, 
the median local control is 20.9 months, and the median time of 
control of the brain outside the SRS field is 13.2 months.
A Cox-proportional hazards model was used for multivariate 
analysis. The model included ECOG PS, control of extracranial 
disease, RPA class, prior GKRS, prior brain metastasectomy, 
prior chemotherapy, number of metastatic lesions, tumor histol-
ogy, and insurance status. On multivariate analysis, ECOG PS 
0–1 prior GKRS and control of extracranial disease remained 
significant predictors of survival, while RPA stage, prior brain 
metastasectomy, the use of prior chemotherapy, and number 
of metastatic lesions did not remain significant. Breast cancer 
vs. other histologies did not remain significant on multivariate 
analysis (Table 3).
DiscUssiOn
We present one of the larger single-institution cohorts of patients 
treated for brain metastases with GKRS. Our data support 
previously published reports that GKRS is an effective treatment 
modality for patients with limited metastatic disease to the brain 
(8, 13–18). In our study, better ECOG performance statues, 
control of extracranial disease, and multiple SRS treatments are 
predictors of improved median overall survival. Ethnicity and 
FigUre 4 | Overall survival based on prior metastasectomy.
FigUre 3 | Overall survival based on number of gamma Knife® 
radiosurgery (gKrs) sessions.
FigUre 2 | Overall survival based on extracranial disease.
FigUre 1 | Overall survival based on ecOg performance status.
4
Harris et al. SRS Brain Metastases
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 90
insurance status are not predictors of worse outcome following 
SRS in our patient population.
In our series, patients with an ECOG PS of ≥2 had a median 
survival time of 1.8 months (Figure 1). The median survival in 
patients with ECOG performance status of ≥2 is comparable to 
the overall survival reported in other studies for patients with 
untreated metastatic disease (19, 20). While radiosurgery may be 
used for symptom palliation, the short overall survival in patients 
with ECOG ≥2 brings to question the additional utility of GKRS 
in such patients over more conservative management. Our series 
also matches previous reports that demonstrate improved overall 
median survival with better control of extracranial disease (21) 
(Figure 2). This series re-enforces the conclusions that these fac-
tors remain strong predictors of survival across different patient 
populations, including our cohort with many non-Caucasian 
patients and patients without private insurance.
Patients who were able to receive multiple GKRS sessions had 
a significantly longer median survival than those treated with a 
single session (Figure 3). There is a strong selection bias in this 
result, as patients who are able to receive additional GKRS are not 
only surviving long enough to have additional follow-up scans but 
also presenting with a limited number of recurrent CNS lesions 
to fit our selection criteria for repeat GKRS vs. WBRT or symp-
tomatic care alone. It is difficult to draw strong conclusions from 
this result at this time, but it does at least appear to support the 
approach of using repeat GKRS in appropriately selected patients 
who have regional recurrence of metastatic disease within the 
brain. Similarly, patients with prior metastasectomy saw a sur-
vival benefit on univariate analysis (although not on multivariate 
analysis) compared to patients with no prior metastasectomy 
(Figure 4). This may also reflect patient selection as patients who 
were candidates for metastasectomy generally presented with a 
single CNS lesion and were clinically regarded as both functioning 
well enough to be able to better tolerate surgery and also having a 
long enough expected overall survival to be more likely to benefit 
from more aggressive local therapy. However, these findings do 
seem to support the studies showing better outcomes in patients 
treated with GKRS to the surgical bed (7).
On univariate analysis, RPA Stage I vs. II–III was a significant 
predictor for improved median survival, but on multivariate 
FigUre 5 | local control.
FigUre 6 | Out-of-gamma Knife® radiosurgery (gKrs) field brain 
control.
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analysis, this was no longer significant. This could be related 
to the fact that the RPA is correlated with ECOG PS and 
control of extracranial disease by definition, and this could have 
confounded the multivariate analysis. Prior chemotherapy vs. 
no prior chemotherapy was another factor that did significantly 
predict survival on multivariate analysis, this could be due to the 
heterogeneity of the clinical scenarios pertaining to whether the 
patient had received prior systemic therapy. The heterogeneity 
of patients may also affect our analysis of outcome by histology, 
although we did find that the survival of breast cancer patients vs. 
all other histologies approached significance, which agrees with 
other publications showing differences in outcome depending on 
histology (22, 23). The number of metastatic lesions of 1–3 vs. ≥4 
approached significance. There is currently debate in the literature 
regarding the importance of the number of brain metastases vs. 
the total tumor volume in predicating overall survival (8, 24, 25). 
The volume of tumor was not part of this current analysis due to 
variation in how tumor/GTV volume was documented, but it can 
be examined more closely in future patients.
Ethnicity and gender were also not predictors of worse 
survival following SRS in our analysis. Previous studies have 
reported inferior outcomes in cancer patients who are uninsured 
or underinsured (6). On univariate analysis, patients who were 
uninsured or with Medicare/Medicaid vs. commercial insur-
ance approached significance (13.7 vs. 6.8 months, p = 0.080); 
however on multivariate analysis, insurance status was no 
longer a significant predictor of overall survival (p  <  0.49). 
This lack of significance could be due in part to the number of 
patients included in our analysis compared to the numbers of 
patients in publications using registry data that showed a worse 
mortality in underinsured patients (10, 11), but it may also 
suggest that the primary drivers of potential health disparity 
in our patient population may be related to their presentation 
in a more advanced disease state (potentially with more active 
extracranial disease, lower PS, etc.), rather than an inability to 
receive adequate care following GKRS. One weakness to our 
study in regard to our analysis of insurance status is the fact 
that only two uninsured patients were included, as explained 
in the Section “Materials and Methods” this was mostly due 
to a more favorable payment schedule available with robotic 
SRS that is also available at our institution and a preference for 
most uninsured patients to choose that modality over GKRS. 
A separate analysis that includes the outcomes of patients treated 
for brain metastases with robotic SRS, especially uninsured 
patients, would be interesting but was unfortunately beyond the 
scope of this particular study. An analysis of local control, brain 
control, or preservation of neurologic function following GKRS 
would also have been informative, but unfortunately since our 
institution treats many patients at considerable geographic 
distance from our center who preferred to continue follow-up 
and additional care with their local oncologists, we did not 
feel as though the quality of the data for those outcomes was 
thorough enough for inclusion in our analysis. We included the 
local control (Figure 5) and out of field brain control (Figure 6) 
curves of the 74 patients with post-GKRS MRIs available for 
review, our rates of control are roughly equivalent to those seen 
in other series (23, 25).
cOnclUsiOn
Gamma Knife SRS is an effective palliative treatment for brain 
metastases in our institutional cohort. ECOG PS 0–1, control of 
extracranial disease, and multiple SRS treatments are predictors 
of longer median overall survival following GKRS. Prior brain 
metastasectomy approached significance in our study. These 
factors may influence patient selection for SRS. Ethnicity and 
insurance status are not predictors of worse outcomes follow-
ing SRS at our institution. Our median survival matches trends 
seen nationally for patients with advanced disease. Prospective 
studies to verify that ethnicity and insurance status do not 
appear to influence the outcomes of patients following GKRS 
are needed.
eThics sTaTeMenT
This study was carried out in accordance with the recommen-
dations of the guidelines for retrospective reviews of the East 
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approved by the East Carolina University Institutional Review 
Board.
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